The whole procedure is very well orchestrated…it's almost like a CIA exploration.
When doctors told Sergei German, 54, that his cancer warranted a watch-and-wait approach, he was unsettled. He knew that people with his type of cancer, follicular lymphoma, can live for many years without treatment, but didn’t like the idea of leaving his fate to chance.
That’s when he decided to seek out clinical trials. He found one he was interested in at Mount Sinai Hospital in New York, being conducted by Joshua Brody, M.D. The clinical trial involves three separate components. The first is injecting the tumor with a molecule, called a cytokine, which recruits dendritic cells (DCs) to the site of the tumor. DCs are known as professional antigen-presenting cells; their main job is picking up foreign and cancerous antigens and presenting them to the “attack” cells of the immune system.
The second part is localized radiation to the tumor to destroy cancer cells and release their distinctive antigens. The final stage is injecting the tumor with an adjuvant molecule that prods the DCs into a frenzy of antigen presentation.
Sergei began the treatment in early 2014. TheAnswertoCancer (TheA2C) spoke with him about what appealed to him regarding this therapy and how it is working for him.
Let's spread the word about Immunotherapy! Click to share this page with your community.